Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding

Tevogen Bio Holdings Inc.

Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.
Funding is non-dilutive and will support development of off-the-shelf T cell therapies for cancers and viral infections.
Tevogen may also use grant to expand AI efforts (Tevogen.AI) in partnership with Microsoft.
KRHP LLC is affiliated with spouse of Dr. Manmohan Patel, an existing >5% beneficial owner of TVGN common stock.
Grant is in addition to previously announced $36M loan agreement from Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.